High-dimensional proteomic analysis for pathophysiological classification of traumatic brain injury.

biomarker inflammation neurodegeneration neuroimaging

Journal

Brain : a journal of neurology
ISSN: 1460-2156
Titre abrégé: Brain
Pays: England
ID NLM: 0372537

Informations de publication

Date de publication:
26 Sep 2024
Historique:
received: 23 04 2024
revised: 06 08 2024
accepted: 24 09 2024
medline: 26 9 2024
pubmed: 26 9 2024
entrez: 26 9 2024
Statut: aheadofprint

Résumé

Pathophysiology and outcomes after Traumatic Brain Injury (TBI) are complex and heterogenous. Current classifications are uninformative about pathophysiology. Proteomic approaches with fluid-based biomarkers are ideal for exploring complex disease mechanisms, as they enable sensitive assessment of an expansive range of processes potentially relevant to TBI pathophysiology. We used novel high-dimensional, multiplex proteomic assays to assess altered plasma protein expression in acute TBI. We analysed samples from 88 participants from the BIO-AX-TBI cohort (n=38 moderate-severe TBI [Mayo Criteria], n=22 non-TBI trauma, n=28 non-injured controls) on two platforms: Alamar NULISA™ CNS Diseases and OLINK® Target 96 Inflammation. Patient participants were enrolled after hospital admission, and samples taken at a single timepoint up to 10 days post-injury. Participants also had neurofilament light, GFAP, total tau, UCH-L1 (all Simoa®) and S100B (Millipore) data. The Alamar panel assesses 120 proteins, most of which were previously unexplored in TBI, plus proteins with known TBI-specificity, such as GFAP. A subset (n=29 TBI, n=24 non-injured controls) also had subacute (10 days to 6 weeks post-injury) 3T MRI measures of lesion volume and white matter injury (fractional anisotropy). Differential Expression analysis identified 16 proteins with TBI-specific significantly different plasma expression. These were neuronal markers (calbindin2, UCH-L1, visinin-like protein1), astroglial markers (S100B, GFAP), neurodegenerative disease proteins (total tau, pTau231, PSEN1, amyloid-beta-42, 14-3-3γ), inflammatory cytokines (IL16, CCL2, ficolin2), cell signalling (SFRP1), cell metabolism (MDH1) and autophagy related (sequestome1) proteins. Acute plasma levels of UCH-L1, PSEN1, total tau and pTau231 correlated with subacute lesion volume. Sequestome1 was positively correlated, whilst CLL2 was inversely correlated, with white matter fractional anisotropy. Neuronal, astroglial, tau and neurodegenerative proteins correlated with each other, IL16, MDH1 and sequestome1. Exploratory clustering (k means) by acute protein expression identified 3 TBI subgroups that differed in injury patterns, but not age or outcome. One TBI cluster had significantly lower white matter fractional anisotropy than control-predominant clusters, but had significantly lower lesion subacute lesions volumes than another TBI cluster. Proteins that overlapped on two platforms had excellent (r>0.8) correlations between values. We identified TBI-specific changes in acute plasma levels of proteins involved in neurodegenerative disease, inflammatory and cellular processes. These changes were related to patterns of injury, thus demonstrating that processes previously only studied in animal models are also relevant in human TBI pathophysiology. Our study highlights how proteomic approaches might improve classification and understanding of TBI pathophysiology, with implications for prognostication and treatment development.

Identifiants

pubmed: 39323289
pii: 7775599
doi: 10.1093/brain/awae305
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of the Guarantors of Brain.

Auteurs

Lucia M Li (LM)

Department of Brain Sciences, Imperial College London, Sir Michael Uren Building, London, W12 0BZ, UK.
UK Dementia Research Institute Centre for Care Research & Technology, Sir Michael Uren Building, London, W12 0BZ, UK.

Eleftheria Kodosaki (E)

Department of Neurodegenerative Disease, UCL Institute of Neurology, London, WC1N 3BG, UK.
UK Dementia Research Institute, UCL, London, W1T 7NF, UK.

Amanda Heslegrave (A)

Department of Neurodegenerative Disease, UCL Institute of Neurology, London, WC1N 3BG, UK.
UK Dementia Research Institute, UCL, London, W1T 7NF, UK.

Henrik Zetterberg (H)

UK Dementia Research Institute, UCL, London, W1T 7NF, UK.
Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, 431 41, Sweden.
Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, 413 45, Sweden.

Neil Graham (N)

Department of Brain Sciences, Imperial College London, Sir Michael Uren Building, London, W12 0BZ, UK.
UK Dementia Research Institute Centre for Care Research & Technology, Sir Michael Uren Building, London, W12 0BZ, UK.

Karl Zimmerman (K)

Department of Brain Sciences, Imperial College London, Sir Michael Uren Building, London, W12 0BZ, UK.
UK Dementia Research Institute Centre for Care Research & Technology, Sir Michael Uren Building, London, W12 0BZ, UK.

Eyal Soreq (E)

Department of Brain Sciences, Imperial College London, Sir Michael Uren Building, London, W12 0BZ, UK.
UK Dementia Research Institute Centre for Care Research & Technology, Sir Michael Uren Building, London, W12 0BZ, UK.

Thomas Parker (T)

Department of Brain Sciences, Imperial College London, Sir Michael Uren Building, London, W12 0BZ, UK.
UK Dementia Research Institute Centre for Care Research & Technology, Sir Michael Uren Building, London, W12 0BZ, UK.

Elena Garbero (E)

Department of Medical Epidemiology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Bergamo, 21056, Italy.

Frederico Moro (F)

Department of Acute Brain and Cardiovascular Injury, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Bergamo, 21056, Italy.

Sandra Magnoni (S)

Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, 07100, Italy.

Guido Bertolini (G)

Department of Medical Epidemiology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Bergamo, 21056, Italy.

David J Loane (DJ)

School of Biochemistry and Immunology, Trinity College Dublin, Dublin 2, Ireland.
Department of Anesthesiology and Shock, Trauma and Anesthesiology (STAR) Research Center, University of Maryland School of Medicine, Baltimore, Maryland, 21201, USA.

David J Sharp (DJ)

Department of Brain Sciences, Imperial College London, Sir Michael Uren Building, London, W12 0BZ, UK.
UK Dementia Research Institute Centre for Care Research & Technology, Sir Michael Uren Building, London, W12 0BZ, UK.

Classifications MeSH